Category: PressRelease

RBDCOV initiates the first Phase III clinical trial of HIPRA’s Covid-19 vaccine in immunocompromised people

Posted on 18 May 202218 May 2022 by rbdcoveu@gmail.com

Posted in PressRelease

Posts navigation

Older posts

Newer posts

Twitter Linkedin Youtube

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.

RBDCOV 2022 © All Rights Reserved.

Protection of personal data

Cookies policy

Legal notice

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. More information in our Cookies Policy.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies Enabled Disabled

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies Enabled Disabled

Cookie Policy

More information about our Cookies Policy